Small molecule challenges dominance of TNF-alpha inhibitors.
Sheridan
Cormac
C
D000631:Aminopyridines; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D004345:Drug Industry / Q000191:economics* / Q000639:trends*; D004465:Economic Competition / Q000191:economics / Q000639:trends; D006801:Humans; D009025:Morpholines; D010078:Oxazines / Q000191:economics* / Q000627:therapeutic use*; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use*; D011743:Pyrimidines; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States
D000631:Aminopyridines; D009025:Morpholines; D010078:Oxazines; D011725:Pyridines; D011743:Pyrimidines; D014409:Tumor Necrosis Factor-alpha; C523665:fostamatinib